Core Viewpoint - The outbreak of Nipah virus in West Bengal, India, highlights the urgent need for rapid and accurate diagnostic and warning capabilities in global public health systems, with a mortality rate of 40% to 75% and no specific treatment or vaccine available [1] Group 1: Company Overview - Huajian Medical is a high-tech intellectual property capital operation platform focused on the life sciences sector, closely monitoring global public health dynamics and providing technical support for the prevention and control of emerging infectious diseases [1] - The company’s subsidiary, Shenzhen Carbonhua Biotechnology Co., Ltd., specializes in molecular diagnostics and aims to provide comprehensive solutions in this field through research, production, and technical services [1] Group 2: Technological Advancements - Carbonhua Biotechnology has developed a dual-platform detection solution for Nipah virus, which includes a rapid screening and precise tracing capability [2] - The intelligent fluorescence PCR rapid detection platform utilizes an AI primer design platform to efficiently identify and lock onto conserved gene regions of high-risk pathogens, ensuring high specificity and sensitivity in detection [2] - The high-throughput sequencing and intelligent analysis platform offers a localized sequencing solution that can detect and differentiate Nipah virus and other coexisting pathogens, completing the process from sample receipt to report generation within 17 hours [3] Group 3: Strategic Implications - The rapid response to Nipah virus detection demonstrates the integrated technological capabilities of Huajian Medical in public health emergencies and is a significant validation of its strategic direction [4] - The company aims to establish a replicable intelligent public health monitoring system adaptable to various emerging infectious diseases and chronic disease management scenarios [4] - The product launch and strategic outline reflect the company's commitment to the core paradigm of "intelligent capital driving continuous knowledge profitability" and enhancing the innovative efficiency and commercial value of enterprises within its ecosystem [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 華檢醫療控股有限公司 ETHK Labs Inc. （於開曼群島註冊成立之有限公司） （前稱 IVD Medical Holding Limited ） （股份代號：1931） 自願性公告 關於子公司成功研發尼帕病毒檢測雙平台解決方案及 集 團AI醫療戰略升級的進展 一、背景與契機 近 日，印 度 西 孟 加 拉 邦 暴 發 尼 帕 病 毒 疫 情，世 界 衛 生 組 織 已 將 其 列 為 致 命 性 人 畜 共 患 病 毒，感 染 死 亡 率 可 達40%至75%，且 目 前 尚 無 特 效 療 法 或 疫 苗。此 類 新 發 突 發 傳 染 病 疫 情 凸 顯 全 球 公 共 衛 生 體 系 對 快 速、精 準 診 斷 與 預 警 能 力 的 迫 切 需 求。 作 為 長 期 深 耕 生 命 科 學 領 域 的 高 科 技 知 識 產 權 資 ...

Core Viewpoint - The recent long-term procurement contract worth 600 million yuan between Mingji Hospital and Hefei China reflects both companies' operational anxieties, with Mingji Hospital needing to implement its expansion plans and Hefei China facing significant performance declines due to industry pressures [1][5][8]. Group 1: Company Performance - Hefei China is experiencing a significant downturn, with a projected revenue decline of 26.67% to 689 million yuan for 2025 and a shift from a net profit of 27.57 million yuan to a loss between 25 million and 36 million yuan [5][7]. - The company's losses are attributed to the implementation of centralized procurement policies in the in vitro diagnostics industry, which have drastically reduced procurement prices and squeezed sales revenue and gross margins [7][11]. - Despite cost control measures, Hefei China is unable to reduce fixed expenses proportionally to its declining revenue, leading to continued financial strain [7][11]. Group 2: Strategic Implications - The partnership between Mingji Hospital and Hefei China is driven by Mingji's urgent need for a stable supply chain to support its expansion plans following its recent IPO, where it raised approximately 555 million HKD [8][11]. - Mingji Hospital's operational model is limited by its higher pricing compared to public hospitals and a narrow customer base, which constrains its growth potential [11][15]. - The exclusive supply agreement with Hefei China may limit Mingji Hospital's ability to negotiate prices and manage costs effectively, especially in a context of increasing centralized procurement [11][12]. Group 3: Contractual Risks - The eight-year procurement agreement includes clauses for price adjustments based on market fluctuations, which could significantly impact Hefei China's profit margins and overall financial health [12][15]. - Payment terms require Hefei China to front nearly four months of payment for supplies, increasing its cash flow pressure amid ongoing losses [13][15]. - The lack of clear fallback provisions in the contract raises concerns about potential disputes and the overall stability of the partnership [12][14].

Group 1 - The core viewpoint of the news is that Beijing Hotgen Biotech Co., Ltd. has seen a stock price increase of 5.05%, reaching 154.89 yuan per share, with a total market capitalization of 14.36 billion yuan [1] - The company specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments, with its main business revenue composition being 70.87% from testing reagents, 19.79% from testing instruments, 8.17% from others, and 1.17% from biological raw materials [1] - The stock trading volume for the day was 2.70 billion yuan, with a turnover rate of 1.92% [1] Group 2 - In terms of fund holdings, Invesco Great Wall Fund has a significant position in Hotgen Biotech, with its fund "Invesco Great Wall Emerging Industries Mixed A" holding 178,500 shares, accounting for 3.7% of the fund's net value, ranking as the tenth largest holding [2] - The fund has a total scale of 487 million yuan and has achieved a year-to-date return of 2.75%, ranking 6142 out of 8861 in its category [2] - The fund manager, Nong Bingli, has been in position for 7 years and 222 days, with the best fund return during his tenure being 174.01% [3]

Core Viewpoint - The stock of Capbio has experienced a consecutive two-day limit-up, indicating strong market interest, particularly due to recent Nipah virus infection cases in Eastern India, which aligns with the company's product offerings in virus detection [1] Group 1: Stock Performance - Capbio's stock reached a limit-up at 13:08 today, with a trading volume of 1.275 billion yuan and a turnover rate of 24.53% [1] Group 2: Product and Market Position - The company possesses Nipah virus nucleic acid test kits, which are relevant for epidemic monitoring and border control [1] - As a leading integrated supplier of molecular diagnostic products and services in China, Capbio has developed products for infectious disease testing, covering clinical diagnosis in hospitals and public health prevention [1] Group 3: Research and Development - Capbio is advancing clinical research on HPV infection treatment, with international product deployment across multiple countries and regions [1] - The diversification of the company's business may enhance market attention and support its operations [1] Group 4: Market Trends - The virus prevention concept sector is gaining market attention, and changes in related demand may provide support for the company's business [1]

Group 1 - The core viewpoint of the news is that Antu Biology's stock has increased by 5.98%, reaching a price of 39.54 yuan per share, with a trading volume of 260 million yuan and a turnover rate of 1.20%, resulting in a total market capitalization of 22.594 billion yuan [1] - Antu Biology, established on September 15, 1999, and listed on September 1, 2016, specializes in the research, production, and sales of in vitro diagnostic reagents and instruments, with its main business revenue composition being 86.63% from reagents, 10.99% from instruments, 1.40% from other sources, and 0.98% from maintenance income [1] - Changjiang Asset Management holds a significant position in Antu Biology through its fund, Changjiang Xuri Mixed A (021015), which held 71,000 shares in the fourth quarter, accounting for 2.47% of the fund's net value, ranking as the tenth largest holding [1] Group 2 - The fund manager of Changjiang Xuri Mixed A (021015) is Shi Zhan, who has been in the position for 4 years and 30 days, with the fund's total asset size being 802 million yuan [2] - During Shi Zhan's tenure, the best fund return was 53.53%, while the worst return was 48.76% [2]

Market Performance - The Sci-Tech 50 Index opened slightly higher on January 26 but experienced a significant drop after an initial rise, closing down by 1.35% at 1532.80 points with a total trading volume of approximately 108.9 billion yuan, a slight decrease from the previous trading day [1] - The Sci-Tech Comprehensive Index also opened slightly higher but fell sharply, closing down by 2.23% at 1857.50 points, with a total trading volume of about 344.9 billion yuan, which was an increase compared to the previous trading day [1] Stock Performance - Among the stocks listed on the Sci-Tech board, 109 stocks rose, accounting for approximately 18.17% of the total, while the majority experienced declines [1] - Notable gainers included Zhijiang Biology, Yike De, Ruihua Tai, and Jindike, which all reached a limit-up of around 20% [2] - In contrast, Xinke Mobile saw the largest decline, dropping by 18.15% [2] Trading Metrics - The average decline for the 600 stocks on the Sci-Tech board was 2.12%, with an average turnover rate of 4.20% and a total trading volume of 344.9 billion yuan, reflecting an average fluctuation of 5.96% [1] - Lanqi Technology had the highest trading volume at 11.289 billion yuan, while ST Pava recorded the lowest at 951.73 million yuan [3] - Yike De led in turnover rate at 30.41%, while Bairen Medical had the lowest turnover rate at 0.22% [4]

Group 1 - The core viewpoint of the news is that Capbio (凯普生物) experienced a significant stock price increase, reaching a limit up of 20.03% on January 26, 2026, with a total market capitalization of 4.687 billion yuan [1] - Capbio has recently announced the acquisition of multiple domestic and international patent authorizations, enhancing its technological barriers and core competitiveness [2] - The actual controller, Ms. Wang Jianyu, has completed an increase in holdings amounting to 18.12 million yuan and plans to continue increasing her stake, signaling confidence in the company's development [2] - The company has expanded its business scope by obtaining production qualifications for Class III in vitro diagnostic reagents and Class II obstetric and gynecological instruments [2] - For the first three quarters of 2025, Capbio reported a narrowing of net losses attributable to shareholders by 51.25%, with operating cash flow increasing by 173.06% to 121 million yuan, indicating an improvement in operational conditions [2] - Capbio, as an integrated supplier of molecular diagnostic products and services, is expected to benefit from the growth in the in vitro diagnostics sector within the biopharmaceutical industry [2] - On the market performance side, the biopharmaceutical sector saw active movements, with Capbio's limit-up creating a certain sector linkage effect [2] - Technical indicators such as the MACD forming a golden cross and breaking through the upper Bollinger Band may attract more capital attention [2] - There was likely a flow of main funds into the stock, contributing to the price surge [2]

Summary of Expert Call on China's IVD Market Industry Overview - **Industry**: In-vitro diagnostics (IVD) market in China - **Expert**: Mr. Fang, an IVD distributor with over 15 years of experience Key Points Market Size and Growth Trends - **Q425 Market Performance**: - **Chemiluminescent immunoassay (CLIA)**: -12% YoY in test volume and -16% YoY in revenue, but showed QoQ recovery as panel test unbundling policies ended [2][8] - **Clinical Chemistry**: -5% YoY in both volume and revenue, with volume-based procurement (VBP) largely completed [2][8] - **Haematology**: +6% YoY in both volume and revenue, driven by high influenza A incidence [2][8] - **Haemostasis**: +5% YoY in both volume and revenue [2][8] - **Molecular Testing**: +9% YoY in revenue, also supported by influenza A [2][9] - **Point of Care Tests (POCT)**: -11% YoY in both volume and revenue, due to a shift to CLIA and suspension of non-compliant prescriptions [2][9] Competitive Landscape - **Channel Inventory**: - CLIA: Global brands have 3 months of sales in inventory, down 2 weeks from Q325; domestic brands have 6-10 weeks [3][14] - Haematology: Mindray and Sysmex have 14 weeks and 5 months of sales in inventory, respectively, expected to reduce in 2026 [3][17] - **Import Substitution**: - Significant gains for domestic companies like Mindray in CLIA and haemostasis, while overseas companies like Roche and Siemens lost market share [3][12][28] 2026 Market Outlook - **Growth Projections**: - **CLIA**: Expected to shrink by 2% YoY despite a 2-3% increase in test volume [4][19] - **Clinical Chemistry**: Anticipated growth of 2% YoY [4][20] - **Haematology**: Expected growth of 5% YoY, assuming no national policy headwinds [4][21] - **Haemostasis**: Expected growth of 6% YoY [4][22] - **Molecular Testing**: Expected growth of 7% YoY [4][23] - **POCT**: Expected decline of 6% YoY [4][24] Policy Impacts - **Testing Fee Unification**: Seen as a major swing factor for market growth in 2026, with potential price cuts of 30-40% for reagents not covered by VBPs [4][35][37] - **VBP Implementation**: Five provinces have initiated VBP programs, with full implementation expected by Q126 [29] Risks and Considerations - **Market Risks**: - Potential for larger-than-expected price reductions and smaller market share gains from VBP programs [40] - Weaker demand from equipment renewal programs and geopolitical issues affecting supply chains [40] Additional Insights - The expert noted that the impact of the Chinese New Year on sales growth was about 5-6% YoY due to later occurrence in 2026 compared to 2025 [7] - The expert expressed a more positive outlook for CLIA in 2026 compared to previous estimates, reflecting recent QoQ recovery [4][24] This summary encapsulates the key insights from the expert call regarding the current state and future outlook of China's IVD market, highlighting growth trends, competitive dynamics, and the impact of policy changes.

Group 1 - The company, Hefei China, expects a net profit loss of between 25 million to 36 million yuan for 2025, compared to a net profit of 27.57 million yuan in the same period last year. The expected non-net profit loss is between 24 million to 35 million yuan [2] - The company's consolidated operating revenue for 2025 is projected to be 689 million yuan, a decrease of 26.67% compared to the previous year [2] - The anticipated losses are attributed to changes in the domestic macro environment and the impact of centralized procurement policies in the in vitro diagnostics industry, leading to reduced product procurement prices and fluctuations in order volumes [2] Group 2 - To address market and business changes, the company is actively adjusting its business layout and development strategy, focusing on the technological iteration and innovation of its "ACME" proprietary products, increasing R&D investment, and expanding its market development team [3] - The company signed a long-term procurement agreement with Nanjing Mingji Hospital and Suzhou Mingji Hospital, committing to a total procurement amount of no less than 600 million yuan over 96 months for in vitro diagnostic reagents and consumables [3] - This contract is expected to positively impact the company's performance in 2026 and beyond, enhancing its sustainable profitability and overall competitiveness [3] Group 3 - The company has indicated that if the procurement prices for in vitro diagnostic reagents and consumables are adjusted during the contract period, the supply prices will also be adjusted proportionally [4] - The contract is a routine operational contract with a long performance period, and the annual procurement amount from Mingji Hospital is expected to be less than 10% of the company's annual revenue, minimizing dependency on this single client [4]